 - Determine whether the addition of bevacizumab to dose-intense capecitabine in combination with alternating full-dose irinotecan hydrochloride and oxaliplatin as first-line treatment leads to an improved response rate in patients with metastatic colorectal cancer compared to that of published results of fluoropyrimidineoxaliplatin, fluoropyrimidineirinotecanbevacizumab, and fluoropyrimidineirinotecan regimens. phase II 